Almac reported revenues were up 8% to £325 million in 2013, and pre-tax profits were £19.2 million, up 30%.
Alan Armstrong, chief executive officer of Almac, said, “2013 was an exciting year for us with a major jobs boost in Craigavon as we completed a non-GMP drug development facility and expanded our manufacturing capabilities, announced a £13 million investment in cancer research projects with Queen’s University and signed a $9 million deal with Genomic Health, securing the rights to further develop and commercialize our breast cancer test.
“We have continued to invest in R&D and capital programs and this year is set to be another successful one both at our headquarters in Craigavon and globally, following the opening of our new offices in Asia, and looking ahead to the launch of our new facility in Singapore early next year,” added Mr. Armstrong.
Almac provides a range of integrated services to companies globally within the pharma and biopharma sectors.The company employs approximately 3,400 people globally, with 2,000 based at its Craigavon Headquarters. The company has a U.S. operation in PA and recently opened regional hubs in Singapore and Japan expanding its services in the Asian market.